Inventor · disambiguated record
Michael Solomon Goldberg
Also filed as: GOLDBERG MICHAEL · GOLDBERG MICHAEL M · GOLDBERG MICHAEL S · GOLDBERG MICHAEL SOLOMON
9 granted patents·17 pending applications·160 citations·filing 1993–2025
89Inventor score
Files withDANA FARBER CANCER INST INC15SURGE THERAPEUTICS INC6ANDERSON DANIEL G1GOLDBERG MICHAEL S1MASSACHUSETTE INST OF TECHNOLOGY1
Top patents by PatentIndex Score
26 records- 0195US10435469B2Drug delivery compositions and uses thereofDANA FARBER CANCER INST INC·Filed 2018·Granted Oct 8, 2019·15 cites·28 claims
- 0295US10413612B2Method of treating cancer with a biomaterial and a toll-like receptor agonistDANA FARBER CANCER INST INC·Filed 2018·Granted Sep 17, 2019·13 cites·28 claims
- 0395US9006487B2Amine-containing lipids and uses thereofANDERSON DANIEL G·Filed 2006·Granted Apr 14, 2015·70 cites·25 claims
- 0494US10836826B2Drug delivery compositions and uses thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 17, 2020·9 cites·26 claims
- 0592US11021539B2Drug delivery compositions and uses thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Jun 1, 2021·7 cites·24 claims
- 0692US11000547B2Compositions related to rna in circularized formDANA FARBER CANCER INST INC·Filed 2016·Granted May 11, 2021·17 cites·30 claims
- 0772US2021246211A1Drug delivery compositions and uses thereofDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 0870US12258560B2Compositions and methods for transient gene therapy with enhanced stabilityDANA FARBER CANCER INST INC·Filed 2021·Granted Mar 25, 2025·0 cites·16 claims
- 0969US2024076309A1Compositions and methods for transient gene therapy with enhanced stabilityDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1067US2025243484A1Compositions and methods for transient gene therapy with enhanced stabilityDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 1162US2005054557A1Compositions for delivering parathyroid hormone and calcitoninFiled 2004·Application pending·0 cites
- 1261US2025049951A1Nucleic acid compositions and uses thereofSURGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1361US2025032478A1Solid forms of resiquimod and formulations thereofSURGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1457US2024082236A1Cancer therapySURGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1555US11753434B2Compositions and methods for transient gene therapy with enhanced stabilityDANA FARBER CANCER INST INC·Filed 2018·Granted Sep 12, 2023·0 cites·8 claims
- 1655US2023293427A1Preparations and compositions comprising polymer combination preparationsSURGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1755US2023398146A1Immune modulation of myeloid derived suppressive cell function for cancer treatmentSURGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1851US2021008048A1Compositions and methods for cancer treatmentDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 1948US2022218822A1Cancer treatmentSURGE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2047US2019262475A1Composition and methods of genome editing of b-cellsDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
- 2147US2016009657A1Amine-containing lipids and uses thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2015·Application pending·0 cites
- 2241US2020179528A9Immune cell-targeted particlesDANA FARBER CANCER INST INC·Filed 2016·Application pending·0 cites
- 2340US2017266123A1Coated particles for drug deliveryDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 2440US2017112777A1Protein-based particles for drug deliveryDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 2538US5341803AApparatus and method for monitoring gastric fluid pHGOLDBERG MICHAEL S·Filed 1993·Granted Aug 30, 1994·29 cites·18 claims
- 2632US2013018086A1Sirnas targeting exon 10 of pyruvate kinase m2MASSACHUSETTE INST OF TECHNOLOGY·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Solomon Goldberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →